查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1771719

mRNA治療合約開發與受託製造廠商市場規模、佔有率、趨勢分析報告：按適應症、應用、最終用途、地區、細分市場預測，2025-2033年

mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Indication (Metabolic & Genetic Diseases), By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 170 Pages | 商品交期: 2-10個工作天內

價格

mRNA 治療合約開發和受託製造廠商市場的成長和趨勢

根據 Grand View Research, Inc. 的新報告，全球 mRNA 療法合約開發和受託製造廠商市場預計到 2033 年將達到 147.5 億美元，2025 年至 2033 年的複合年成長率為 15.22%。

mRNA 和細胞遞送系統技術日新月異，加之其成本效益高、易於生產以及能夠靶向此前無法治癒的途徑，擁有無限潛力，有望徹底改變醫療保健行業。這對市場而言可能是一個利潤豐厚的成長機會。不斷增加的研發投入用於開發 mRNA 療法以及強大的產品平臺也推動市場的成長。例如，Moderna 宣布其 2023 年第四季的研發費用達到 14 億美元，較 2022 年同期成長 16%。

研發費用的成長主要源自於公司巨細胞病毒(CMV) 疫苗、呼吸道合胞病毒 (RSV) 疫苗、新冠肺炎 (COVID-19) 和流感聯合疫苗以及個人化腫瘤抗原治療的臨床生產活動增加。這些因素預計將推動 mRNA 療法的研究力度。此外，為滿足尚未滿足的醫療需求而開發的新型療法正在改變產品市場。隨著分子複雜性的增加，對研發和生產服務的深度了解，以及能夠實現新型分子形式永續表達和規模化生產的技術的需求日益成長。生物偶聯和雙特異性抗體生成等平台技術可以顯著縮短開發和生產時間，客戶正在尋求能夠加快產品上市時間並降低投資風險的經驗豐富的合約研發生產組織 (CDMO)。因此，製藥生物技術產業對 CDMO 設計和生產產品的需求正在呈指數級成長。

mRNA 治療合約開發和受託製造廠商市場亮點

  • 病毒疫苗領域將在 2024 年佔據最大佔有率。該領域的成長可歸因於用於治療病毒感染（COVID-19）的各種疫苗的可用性和推出的增加。
  • 由於感染疾病率不斷上升、mRNA 疫苗相較於傳統疫苗的許多優勢、新興的臨床研究和管道分析，以及製藥公司之間生產合作的不斷加強和市場細分，預計感染疾病領域將在 2024 年佔據最大的市場佔有率。
  • 生物技術最終用途領域將主導市場，到 2024 年將佔 62.34% 以上的佔有率。該領域的成長受到日益增多的策略性舉措的推動，例如與 CDMO 建立合作夥伴關係並合作生產 mRNA 疫苗。
  • 預計亞太地區mRNA療法受託製造廠商市場在預測期內將實現顯著的複合年成長率。由於印度和中國等開發中國家製藥公司和受託製造廠商數量的不斷增加，亞太地區在不久的將來很可能超越歐洲和北美。

目錄

第1章調查方法與範圍

第2章執行摘要

第 3 章 mRNA 治療合約開發與受託製造廠商的市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/支持市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 定價模式分析
  • 科技
  • 市場分析工具
    • 波特五力分析
    • PESTEL 與 SWOT 分析
    • COVID-19影響分析

第4章 mRNA 治療合約開發和受託製造廠商市場：按適應症的估計和趨勢分析

  • mRNA 治療合約開發與受託製造廠商市場（按適應症）：細分儀表板
  • mRNA 治療合約開發與受託製造廠商市場（按適應症）：波動分析
  • 依適應症，2021-2033年
  • 感染疾病
  • 代謝和遺傳疾病
  • 心臟和腦血管疾病

第5章 mRNA 治療合約開發和受託製造廠商市場：按應用進行的估計和趨勢分析

  • mRNA 治療合約開發與受託製造廠商市場（按應用）：細分儀表板
  • mRNA 治療合約開發與受託製造廠商市場（按應用）：波動分析
  • 按應用，2021-2033 年
  • 病毒疫苗
  • 蛋白質替代療法
  • 癌症免疫治療

第6章 mRNA 治療合約開發和受託製造廠商市場：按最終用途分類的估計和趨勢

  • mRNA 治療合約開發和受託製造廠商市場（按最終用途）：細分儀表板
  • mRNA 治療合約開發與受託製造廠商市場（以最終用途）：變異分析
  • 依最終用途，2021-2033 年
  • 生技公司
  • 製藥公司
  • 政府及學術研究機構

第7章 mRNA 治療合約開發和受託製造廠商市場：按地區估計和趨勢分析

  • 區域市場儀表板
  • 2024 年及 2033 年區域市場佔有率分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 泰國
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 市場參與企業分類
  • 2024 年公司市場佔有率/估值分析
  • 公司簡介
    • Danaher（Aldevron）
    • Biomay AG
    • Bio-Synthesis, Inc.
    • eTheRNA
    • Kaneka Eurogentec SA
    • TriLink BioTechnologies
    • ApexBio Technology
    • BioNTech SE
    • Biocina
    • Lonza
    • Recipharm AB
    • Novo Holdings（Catalent, Inc.）
    • Samsung Biologics
Product Code: GVR-4-68040-083-7

mRNA Therapeutics Contract Development & Manufacturing Organization Market Growth & Trends:

The global mRNA therapeutics contract development & manufacturing organization market size is estimated to reach USD 14.75 billion by 2033, expanding at a CAGR of 15.22% from 2025 to 2033, according to a new report by Grand View Research, Inc. Growing technological advancements in mRNA and cellular delivery systems, coupled with their cost effectiveness, manufacturing simplicity, and ability to target previously undruggable pathways, have limitless potential to revolutionize medicine. This could represent lucrative growth opportunities for the market. Increasing R&D investments to develop mRNA therapeutics and a strong product pipeline are also propelling the market's growth. For instance, Moderna shared that R&D expenses for the fourth quarter of 2023 increased by 16% to USD 1.4 billion compared to the same quarter of 2022.

The R&D spending was driven by increased clinical manufacturing activities, with the company's Cytomegalovirus (CMV) vaccine, RSV vaccine, and combination vaccine against COVID-19 & flu, as well as its individualized neoantigen therapy. Such factors are expected to boost research efforts in mRNA therapeutics. In addition, developing novel therapeutics to address unmet medical needs is altering the product market. The rise in molecular complexity drives the need for in-depth knowledge in research and manufacturing services, as well as the technology to enable sustainable expression and scale-up of novel molecular formats. Platform technologies, such as those for bioconjugation or the creation of bispecific antibodies, can drastically shorten development and production times, and customers are looking for skilled CDMOs who can assist them shorten the time to market and reducing investment risk. Consequently, the need for CDMOs to design and produce goods for the pharmaceutical and biotechnology industries is growing exponentially.

mRNA Therapeutics Contract Development & Manufacturing Organization Market Report Highlights:

  • The viral vaccines segment accounted for the largest share in 2024. Growth in the segment can be attributed to the rising availability and launch of various vaccines for the treatment of viral infection (COVID-19)
  • The infectious diseases segment held the largest market share in 2024 due to the growing incidence of infectious diseases, several advantages of mRNA vaccine over conventional vaccines, emerging clinical studies & pipeline analysis, and increasing collaboration between pharmaceutical companies & CDMO for production
  • The biotech companies end-use segment dominated the market and accounted for a share of more than 62.34% in 2024. The segment growth is driven by increasing strategic initiatives, such as partnerships & collaborations with CDMOs, to manufacture mRNA vaccines
  • The mRNA therapeutics contract development & manufacturing organization market in Asia Pacific is expected to grow at a significant CAGR over the forecast period. Due to the rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Application
    • 1.2.3. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Value-Chain-Based Sizing & Forecasting
    • 1.7.3. Multivariate Model Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. mRNA Therapeutics Contract Development & Manufacturing Organization Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rapid adoption of mRNA in vaccine development
      • 3.2.1.2. Multiple research efforts on mRNA therapeutics
      • 3.2.1.3. Major funding for mRNA research
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Availability of low-cost substitute therapies
      • 3.2.2.2. High research cost
  • 3.3. Pricing Model Analysis
  • 3.4. Technology Landscape
  • 3.5. Market Analysis Tools
    • 3.5.1. Porter's Five Force Analysis
    • 3.5.2. PESTEL by SWOT Analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. mRNA Therapeutics Contract Development & Manufacturing Organization Market: Indication Estimates & Trend Analysis

  • 4.1. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By Indication: Segment Dashboard
  • 4.2. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By Indication: Movement Analysis
  • 4.3. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million)
  • 4.4. Infectious Diseases
    • 4.4.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Metabolic & Genetic Diseases
    • 4.5.1. Metabolic & Genetic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Cardiovascular & Cerebrovascular Diseases
    • 4.6.1. Cardiovascular & Cerebrovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. mRNA Therapeutics Contract Development & Manufacturing Organization Market: Application Estimates & Trend Analysis

  • 5.1. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By Application: Segment Dashboard
  • 5.2. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By Application: Movement Analysis
  • 5.3. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates & Forecasts, By Application, 2021 - 2033 (USD Million)
  • 5.4. Viral Vaccines
    • 5.4.1. Viral Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Protein Replacement Therapies
    • 5.5.1. Protein Replacement Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Cancer Immunotherapies
    • 5.6.1. Cancer Immunotherapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. mRNA Therapeutics Contract Development & Manufacturing Organization Market: End Use Estimates & Trend Analysis

  • 6.1. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By End Use: Segment Dashboard
  • 6.2. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By End Use: Movement Analysis
  • 6.3. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
  • 6.4. Biotech Companies
    • 6.4.1. Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Pharmaceutical companies
    • 6.5.1. Pharmaceutical companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Government & Academic Research Institutes
    • 6.6.1. Government & Academic Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. mRNA Therapeutics Contract Development & Manufacturing Organization Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2033
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. U.S
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Regulatory Framework
      • 7.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Framework
      • 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Australia
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Share/Assessment Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Danaher (Aldevron)
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Biomay AG
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Bio-Synthesis, Inc.
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. eTheRNA
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Kaneka Eurogentec S.A.
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. TriLink BioTechnologies
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. ApexBio Technology
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. BioNTech SE
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Biocina
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Lonza
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. Recipharm AB
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Service Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Novo Holdings (Catalent, Inc.)
      • 8.3.12.1. Company Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Service Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. Samsung Biologics
      • 8.3.13.1. Company Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Service Benchmarking
      • 8.3.13.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 4. Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 5. Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 6. Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
  • Table 7. North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 8. North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 9. North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 10. North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 11. U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 12. U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 13. U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 14. Canada mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 15. Canada mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 16. Canada mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 17. Mexico mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 18. Mexico mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 19. Mexico mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 20. Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 21. Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 22. Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 23. Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 24. UK mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 25. UK mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 26. UK mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 27. Germany mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 28. Germany mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 29. Germany mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 30. France mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 31. France mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 32. France mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 33. Italy mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 34. Italy mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 35. Italy mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 36. Spain mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 37. Spain mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 38. Spain mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 39. Denmark mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 40. Denmark mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Therapeutics Area, 2021 - 2033 (USD Million)
  • Table 41. Denmark mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 42. Sweden mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 43. Sweden mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 44. Sweden mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 45. Norway mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 46. Norway mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 47. Norway mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 48. Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 49. Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 50. Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 51. Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 52. Japan mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 53. Japan mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 54. Japan mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 55. China mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 56. China mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 57. China mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 58. India mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 59. India mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Therapeutics Area, 2021 - 2033 (USD Million)
  • Table 60. India mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 61. Thailand mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 62. Thailand mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 63. Thailand mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 64. South Korea mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 65. South Korea mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 66. South Korea mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 67. Australia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 68. Australia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 69. Australia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 70. Latin America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 71. Latin America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 72. Latin America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 73. Latin America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 74. Brazil mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 75. Brazil mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 76. Brazil mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 77. Argentina mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 78. Argentina mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 79. Argentina mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 80. Middle East & Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 81. Middle East & Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 82. Middle East & Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 83. Middle East & Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 84. South Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 85. South Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 86. South Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 87. Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 88. Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 89. Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 90. UAE mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 91. UAE mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 92. UAE mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 93. Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 94. Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
  • Table 95. Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 mRNA Therapeutics Contract Development & Manufacturing Organization Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 mRNA Therapeutics Contract Development & Manufacturing Organization Market: Indication outlook and key takeaways
  • Fig. 20 mRNA Therapeutics Contract Development & Manufacturing Organization Market: Indication movement analysis
  • Fig. 21 Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Metabolic & Genetic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Cardiovascular & Cerebrovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 mRNA Therapeutics Contract Development & Manufacturing Organization Market: Application outlook and key takeaways
  • Fig. 25 mRNA Therapeutics Contract Development & Manufacturing Organization Market: Application movement analysis
  • Fig. 26 Viral Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Protein Replacement Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Cancer Immunotherapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 mRNA Therapeutics Contract Development & Manufacturing Organization Market: End Use outlook and key takeaways
  • Fig. 30 mRNA Therapeutics Contract Development & Manufacturing Organization Market: End Use movement analysis
  • Fig. 31 Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Pharmaceutical companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Government & Academic Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Regional Marketplace: Key Takeaways
  • Fig. 35 North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 Canada mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 UK mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Germany mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 France mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Italy mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Spain mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Norway mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Japan mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 China mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 India mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Thailand mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 South Korea mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Australia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 MEA mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 UAE mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key company categorization
  • Fig. 87 Service heat map analysis
  • Fig. 88 Strategic framework